4-AcO-MiPT (4-acetoxy-N-methyl-N-isopropyltryptamine) is a synthetic psychedelic tryptamine and acetylated prodrug of 4-HO-MiPT (miprocin). It belongs to the same structural class as psilocybin — the 4-acylated tryptamine family — but features a methyl and an isopropyl group on the terminal amine rather than psilocybin's two methyl groups. Like other members of this family, it is presumed to be metabolically converted to its 4-hydroxy counterpart (4-HO-MiPT) following ingestion, which then acts at serotonin 5-HT2A receptors to produce psychedelic effects.
Community reports characterize 4-AcO-MiPT as a visually and psychedelically rich compound with a character sometimes described as more "clear-headed" or intellectually stimulating than 4-AcO-DMT. Users note geometric visual phenomena, enhanced pattern recognition, emotional warmth, and a quality of mental clarity that persists at moderate doses. It is frequently described as more manageable than equivalent doses of 4-AcO-DMT, with a somewhat shorter and gentler come-up. Duration is typically 4–6 hours, consistent with the broader 4-AcO compound family.
As with other 4-AcO tryptamines, 4-AcO-MiPT is available primarily through the research chemical market. It is not subject to systematic clinical research, and its safety profile is inferred from structural class membership and accumulated community experience rather than formal study.
Safety at a Glance
High Risk- Source and Verify
- Test with Ehrlich reagent (purple/violet for indole compounds). Purchase from documented, reputable research chemical...
- Toxicity: Acute Toxicity No formal toxicological data in humans. Based on class membership and community experience, acute phys...
- Overdose risk: Fatal overdose from 4-AcO-MiPT alone, at doses within the typical recreational range, is extremel...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 8 hrsHow It Feels
The onset of 4-AcO-MiPT arrives like a slow warming from within. Twenty to forty minutes after ingestion, a deep, radiating warmth begins to build in the core of the body, spreading outward through the limbs in soft waves. The warmth is not merely thermal — it carries an emotional quality, a sense of comfort and safety that softens the edges of anxiety and self-consciousness. There may be mild nausea in the first half hour, but it usually passes quickly, replaced by a pleasant heaviness in the limbs and a tingling in the fingertips and scalp.
As the experience unfolds over the next hour, visual changes begin to emerge. Colors intensify and soften simultaneously — they become more saturated but also warmer, as though the entire visual field has been lit by candlelight. Surfaces develop a gentle breathing quality, expanding and contracting in slow, organic rhythms. Closed-eye visuals are rich and detailed: flowing rivers of warm color, intricate mandala-like structures that pulse with quiet energy, and occasionally vivid, dreamlike scenes that unfold with narrative coherence. There is an introspective pull that is not forced or heavy but rather inviting — the mind turns inward willingly, drawn toward self-examination by curiosity rather than compulsion.
The peak, which arrives around ninety minutes and lasts two to three hours, reveals the compound's most distinctive quality: a warm, enveloping introspection that feels nurturing rather than confrontational. Difficult memories or unresolved emotions may surface, but they arrive wrapped in a compassionate clarity that makes them easier to sit with and examine. The body continues to feel warm and held. Touch becomes deeply pleasurable — not in a stimulated, electric way, but with a slow, intimate tenderness. Music resonates on an emotional level that can bring unexpected tears or quiet joy.
The descent is gentle and extended, the warmth slowly cooling to a pleasant ambient temperature over two to three hours. The introspective depth gradually shallows, leaving behind clear insights and a sense of emotional housekeeping. Physical tiredness arrives softly, and the afterglow carries a quality of tender openness — the world feels a little more beautiful, a little more worthy of attention, and the self feels a little more understood.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(12)
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Runny nose— Excessive nasal discharge commonly occurring during opioid withdrawal or from nasal irritation cause...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Tactile(1)
- Spontaneous tactile sensations— Unprompted physical sensations that arise without external touch or stimulus, manifesting as tinglin...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(18)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Autonomous voice communication— Autonomous voice communication is the experience of hearing and engaging in conversation with one or...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Enhancement and suppression cycles— Enhancement and suppression cycles is a distinctive cognitive effect in which the mind alternates be...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(2)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Prodrug Conversion
4-AcO-MiPT undergoes esterase-mediated hydrolysis of the acetyl group to yield 4-HO-MiPT (miprocin) as the primary active metabolite. The methyl-isopropyl substitution pattern distinguishes it from the dimethyl (DMT/psilocin), diethyl (DET), and diisopropyl (DiPT) analogs. The mixed alkyl substitution is hypothesized to affect receptor binding geometry in ways that contribute to the compound's characteristic profile.
5-HT2A Partial Agonism
4-HO-MiPT acts as a partial agonist at serotonin 5-HT2A receptors. This mechanism is shared across the classical psychedelic tryptamines and phenethylamines. The downstream effects — increased prefrontal glutamate release, disruption of predictive coding, and the characteristic alterations of perception and cognition — are common to the class.
The methyl-isopropyl substitution pattern of MiPT analogs may impart a somewhat different binding profile compared to more symmetrical analogs (dimethyl, diethyl, diisopropyl). This could contribute to the profile differences described by community users — the relatively clear-headed quality and visual emphasis compared to some other 4-AcO compounds.
Additional Targets
Like most tryptamine psychedelics, 4-HO-MiPT likely interacts with multiple serotonin receptor subtypes beyond 5-HT2A, including 5-HT1A (anxiolytic, temperature regulation), 5-HT2C, and trace amine receptors. The relative contributions of these interactions to the subjective experience are not well characterized.
Pharmacokinetics
Onset: 30–75 minutes. Peak: 2–3 hours. Duration: 4–6 hours. No formal pharmacokinetic data available. Rapid functional tolerance with cross-tolerance to other serotonergic psychedelics.
Detection Methods
Urine Detection
4-AcO-MiPT is not targeted by standard immunoassay-based urine drug screens. As a prodrug, 4-AcO-MiPT is rapidly hydrolyzed in vivo to its corresponding 4-HO (psilocin-type) metabolite, and it is primarily this metabolite that would be detected in biological specimens. Specialized LC-MS/MS methods can detect 4-substituted tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The detection window is relatively short compared to many other drug classes due to the rapid hepatic metabolism and renal clearance of tryptamine compounds. Psilocin (4-HO-DMT) is the most commonly targeted analyte in specialized tryptamine panels, and structural analogs may or may not be captured depending on the specific method.
Blood and Serum Detection
Blood detection windows for 4-AcO-MiPT are short, typically 4 to 12 hours after oral ingestion. Peak plasma concentrations of the active metabolite occur within 1 to 2 hours. The rapid first-pass metabolism means that parent compound concentrations in blood are often negligible for 4-AcO prodrugs, while 4-HO compounds themselves are measured directly. LC-MS/MS is required for reliable serum detection at the low concentrations involved.
Standard Drug Panel Inclusion
4-AcO-MiPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for any of the standard panel analytes (amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, benzodiazepines, or barbiturates). Detection requires a specific request for tryptamine or novel psychoactive substance testing at a reference laboratory. Some extended forensic panels include psilocin, which may capture certain 4-substituted tryptamines, but this coverage is not guaranteed for all structural variants.
Confirmatory Methods
Confirmatory identification of 4-AcO-MiPT relies on LC-MS/MS with reference standards specific to the compound or its expected metabolites. GC-MS can also be used following appropriate derivatization. Immunoassay-based methods for psilocybin and psilocin exist but show variable cross-reactivity with structural analogs and are not considered reliable for novel 4-substituted tryptamines. Reference laboratories specializing in novel psychoactive substances offer the most comprehensive detection capabilities.
Reagent Testing (Harm Reduction)
The Ehrlich reagent is the primary harm reduction tool for 4-AcO-MiPT. A sample placed on the reagent should produce a purple to violet color change, confirming the presence of an indole ring system characteristic of tryptamines. This reaction is shared with LSD, psilocybin, DMT, and all indole-containing compounds, so it confirms the general class but not the specific identity. The Hofmann reagent provides a confirmatory blue to violet reaction for tryptamines. The Marquis reagent typically shows no reaction or a dark brown discoloration with 4-substituted tryptamines. A positive Ehrlich result significantly reduces the probability that the substance is a dangerous substitute such as an NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
4-AcO-MiPT's origins trace to the systematic investigation of 4-acetoxy tryptamine analogs initiated by Albert Hofmann and Franz Troxler at Sandoz in the 1960s and later extended by Alexander Shulgin's independent research. The compound belongs to the family of synthetic 4-AcO analogs that emerged from mapping the N-alkyl substitution space around the psilocybin core structure.
Research Chemical Era
Like other 4-AcO tryptamines, 4-AcO-MiPT entered the research chemical market in the 2000s following the growth of online psychedelic communities and the documentation of tryptamine pharmacology in TiHKAL. It occupies a niche within the broader 4-AcO family — less prominent than 4-AcO-DMT but valued for its distinct character.
Community Documentation
Community experience documentation for 4-AcO-MiPT continues to grow through harm reduction forums and experience report databases. The compound's profile — visually rich, relatively clear-headed, moderate duration — has made it a point of interest for experienced tryptamine users exploring the space of 4-AcO analogs. No formal clinical research has examined the compound, and pharmacological characterization remains largely inferential.
Harm Reduction
Source and Verify
Test with Ehrlich reagent (purple/violet for indole compounds). Purchase from documented, reputable research chemical suppliers.
Dosing
- Threshold: 5 mg |Low: 10–15 mg |Common: 15–25 mg |Strong: 25–35 mg
- Begin at 10–15 mg for first experiences. Wait a full 90 minutes before assessing whether effects are as expected.
- Weigh on a milligram-accurate scale. Do not estimate powder quantities.
Set and Setting
Standard serotonergic psychedelic harm reduction applies: comfortable, familiar environment; stable, well-prepared mindset; trusted sober companion ideally present; no obligations for the session day and the day following.
The relatively clear-headed quality described by community users suggests 4-AcO-MiPT may be well suited to structured sessions with intention (journaling, artistic activities, meaningful conversation) rather than purely recreational contexts.
Difficult Experiences
If an experience becomes overwhelming, benzodiazepines (diazepam 10–20 mg) safely reduce intensity. Change of environment, grounding techniques, and the reassurance of a trusted sober companion are first-line responses.
After the Experience
Integration — making meaning from psychedelic experiences — is where lasting benefit appears to arise. Allow recovery time, engage in journaling or conversation, and do not rush back into ordinary obligations.
Toxicity & Safety
Acute Toxicity
No formal toxicological data in humans. Based on class membership and community experience, acute physiological toxicity at psychedelic doses is presumed low, consistent with the broader 4-hydroxy tryptamine family.
Physiological Effects
Mild sympathomimetic effects standard to the tryptamine class: mydriasis, mild tachycardia, possible nausea during onset. The nausea with 4-AcO-MiPT is generally described as less prominent than with some other tryptamines, though this varies individually. Temperature dysregulation (alternating warmth and chills) is commonly reported during onset.
Psychological Risks
- Anxiety and difficult experiences — Less commonly reported than with stronger, longer tryptamines, but possible especially at higher doses or in poorly prepared settings.
- Cognitive impairment — Decision-making, memory, and coordination are significantly impaired during the experience; planning for this is essential.
- Psychosis risk — Standard contraindication for psychotic or bipolar I disorders applies.
Drug Interactions
- MAOIs — Potentiation; serotonin syndrome risk; contraindicated.
- Lithium — Seizure risk; contraindicated.
- Cannabis — Unpredictable intensity amplification.
- Stimulants — Increased cardiovascular stress and anxiety.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 4-AcO-MiPT alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Due to its relative obscurity, the possession and sale of 4-AcO-MiPT is unscheduled in most countries.
Germany: 4-AcO-MiPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 4-AcO-MiPT are punishable as an incitement to place it on the market.
Japan: 4-AcO-MiPT is a controlled substance in Japan effective March 25th, 2015.
Sweden: 4-AcO-MiPT is classified as "health hazard" under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated to the "Act on the Prohibition of Certain Goods Dangerous to Health"). The drug is listed in their regulation SFS 2005:733, making it illegal to sell or possess.
Switzerland: 4-AcO-MiPT could be considered an ester analog of 4-HO-MiPT, which would make it illegal according to Buchstabe B.
United Kingdom: 4-AcO-MiPT is a Class A drug in the UK as it is an ester of the drug 4-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
United States: 4-AcO-MiPT is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelic
Tryptamine
4-HO-MiPT
MiPT
4-AcO-MiPT (Wikipedia)
4-AcO-MiPT (Erowid Vault)
4-AcO-MiPT (Isomer Design)
Discussion
The Big & Dandy 4-AcO-MiPT Thread (Bluelight)
Experience Reports (1)
Tips (3)
Do not combine 4-AcO-MiPT with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of 4-AcO-MiPT for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
Use a milligram scale to weigh 4-AcO-MiPT if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
See Also
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 4-AcO-MiPT - TripSit Factsheet
TripSit factsheet for 4-AcO-MiPT
tripsit - 4-AcO-MiPT - Wikipedia
Wikipedia article on 4-AcO-MiPT
wikipedia